SOURCE: Crystal Research Associates, LLC

Crystal Research Associates, LLC

January 25, 2010 08:30 ET

Crystal Research Associates, LLC Issues Executive Informational Overview® (EIO®) on CEL-SCI Corp.

NEW YORK, NY--(Marketwire - January 25, 2010) - Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview® (EIO®) on CEL-SCI Corp. (NYSE Amex: CVM). The full 64-page report can be found at www.crystalra.com.

CEL-SCI Corp. ("CEL-SCI" or "the Company") develops cancer and infectious disease products that empower immune system defenses. CEL-SCI is organized into three business units: (1) Multikine®, a non-toxic immunotherapy with Orphan Drug status that is poised to enter a global, open-label Phase III trial for advanced primary head and neck cancer; (2) Treatment Vaccines, which includes an H1N1 (pandemic influenza) treatment that entered a clinical study in November 2009 as well as a preclinical treatment vaccine for rheumatoid arthritis (RA); and (3) Contract Manufacturing Services using the Company's new manufacturing facility to generate near-term revenue.

CEL-SCI's lead candidate, Multikine®, is a patented mix of biologically active natural cytokines and is the first of a new class of cancer immunotherapy drugs called immune simulators, which are designed to closely mimic the body's natural immune system. Unlike other immunotherapies, Multikine® is multi-targeted -- it activates multiple cellular components of the immune system to fight cancer -- and is administered to patients before any other treatment, when the immune system is strongest (namely before the patient receives surgery, chemotherapy, or radiotherapy). It has been shown to kill roughly 50% of tumor cells before the standard of care commences and renders residual cancer cells that survive treatment more susceptible to radiation and chemotherapy. In over 200 patients treated to date, Multikine® has been reported to be safe and well tolerated, improving patients' overall survival by 33% at a median of 3.5 years following surgery versus that attained using the standard of care without Multikine® (surgery plus radiation or surgery plus combined chemoradiotherapy).

CEL-SCI plans to begin the Phase III trial of Multikine® at multiple centers in North America, the European Union (EU), South America, and Asia in the summer of 2010. The Company believes that a positive Phase III outcome could enable Multikine® to be routinely included as part of the standard of care for all advanced primary head and neck cancer patients.

About Crystal Research Associates, LLC

Crystal Research Associates, LLC is an independent research firm that provides institutional-quality, fee-based research to small and mid-cap companies. Crystal Research Associates' unique and novel product, the Executive Informational Overview® (EIO®), is free of investment ratings, target prices, and forward-looking financial models. The EIO® presents a crystal clear, detailed report on a company (public or private) in a manner that is easily understood by the Wall Street financial community. The EIO® details a company's product/technology/service offerings, market size(s), key intellectual property, leadership, growth strategy, competition, risks, financial statements, key events, and other such fundamental information. Crystal Research Associates has offices in New York City, West Palm Beach, Montréal, and Toronto. Crystal Research Associates has been compensated by the Company in cash of sixty thousand dollars and two hundred thousand Options/Warrants to purchase CEL-SCI stock for its services in creating and updating the base report, for updates, and for printing costs.

Forward-Looking Safe Harbor Statement

Statements in this news release regarding future financial and operating results, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements including, limited operating history, need for future capital, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports, including forms filed with the SEC.

These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates assumes no obligation to update any of the forward-looking statements in this release.

Contact Information

  • Contact:

    Jeffrey J. Kraws/Karen B. Goldfarb
    Crystal Research Associates, LLC
    P: (609) 306-2274
    F: (609) 395-9339